门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究*

doi:10.3969/j.issn.1672-5069.2018.06.026

摘要/Abstract

摘要： 目的研究应用门冬氨酸鸟氨酸注射液治疗对肝癌切除术患者肝脏缺血再灌注损伤的保护作用。方法 2015年8月~2017年3月我院行择期肝癌切除术患者101例,采用随机数字表法将患者分为对照组50例和试验组51例。术后,给予两组血制品和护肝治疗,另给试验组门冬氨酸鸟氨酸注射液静脉滴注治疗7 d。采用硫代巴比妥酸法测定丙二醛（MDA）,采用黄嘌呤氧化酶法测定超氧化物歧化酶（SOD）,采用酶联免疫法测定一氧化氮（NO）和内皮素-1（ET-1）。结果治疗后,试验组血清MDA水平显著低于对照组[（5.4±0.6） μmol/L对（7.3±0.9）μmol/L],ET-1水平显著低于对照组[（115.2±14.3） pg/L 对（216.6±26.8） pg/L],而试验组血清SOD水平显著高于对照组[（18.6±2.3） U/mL 对（13.3±1.6） U/mL],NO水平也显著高于对照组[（37.9±5.7） μmol/L对（22.5±3.1）μmol/L],差异均有统计学意义（P<0.05）;试验组血清胆红素水平为（23.4±7.7）μmol/L ,显著低于对照组的（31.3±7.8） μmol/L（P<0.05）;观察组患者呼吸频次显著慢于对照组（P<0.05）,而两组血常规变化无显著性差异（P>0.05）。结论应用门冬氨酸鸟氨酸注射液能够减轻肝癌切除术患者肝脏缺血再灌注损伤,保护肝功能,可能与其能够提高机体对氧自由基的清除能力、抑制过氧化反应和恢复肝脏代谢有关。

关键词: 原发性肝癌, 肝癌切除术, 门冬氨酸鸟氨酸, 缺血再灌注损伤, 疗效

Abstract: Objective To investigate the protective effect of aspartate ornithine on hepatic ischemic reperfusion injury in patients with primary liver cancer （PLC）. Methods 101 patients with PLC were recruited in our hospital between August 2015 and March 2017,and all patients with PLC received partial resection of hepatectomy. After operation,the patients were divided into control （n=50） and observation （n=51） group,receiving conventional supporting treatment and those in the observation was treated with intravenous ornithine aspartate injection. Serum malondialdehyde （MDA）,superoxide dismutase （SOD）,nitric oxide （NO） and endothelin-1（ET-1） levels were assayed. Results At the end of 7 day treatment,serum MDA level was significantly lower than in the control [（5.4±0.6） μmol/L vs.（7.3±0.9） μmol/L],serum ET-1 level was also significantly lower than in the control [（115.2±14.3） pg/L vs.（216.6±26.8） pg/L],while serum SOD level in the observation was much higher than in the control[（18.6±2.3） U/mL vs.（13.3±1.6） U/mL],and serum NO level was also significantly higher than in the control [（37.9±5.7） μmol/L vs. （22.5±3.1）μmol/L,P<0.05];serum bilirubin level in the observation group was （23.4±7.7）μmol/L,much lower than in the control[（31.3±7.8） μmol/L,P<0.05];there was no significant difference as respect to the routine blood parameters in the two groups（P>0.05）. Conclusion The application of ornithine aspartate might reduce hepatic ischemia-reperfusion injury after surgical tumor resection in patients with PLC, attributed to the protection of liver function by relieving oxygen free radical and peroxidation injury.

Key words: Hepatoma, Hepatectomy, Ornithine aspartate, Ischemia reperfusion injury, Therapy

闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.

Yan Shuming, Wang Jianguo, Li, Zexin, et al.. Protective effect of aspartate ornithine on hepatic ischemic reperfusion injury in patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 932-935.

参考文献

[1] Barlas AM, Kismet K, Erel S,et al.Erdosteine ameliorates the harmful effects of ischemia-reperfusion injury on the liver of rats. Acta Cir Bras,2017,32(10):796-806.
[2] Jeong JS,Kim D,Kim KY,et al.Ischemic preconditioning produces comparable protection against hepatic ischemia/reperfusion injury under isoflurane and sevoflurane anesthesia in rats. Transplant Proc,2017,49(9):2188-2193.
[3] 甘信利, 胡志高,何松青. 肝脏缺血再灌注损伤的机制研究进展. 中华实验外科杂志,2015,32(11):2906-2907.
[4] Wu S,Zhu X,Jin Z,et al.The protective role of montelukast against intestinal ischemia-reperfusion injury in rats. Sci Rep,2015,5:15787.
[5] Lucas ML,Rhoden CR,Rhoden EL,et al.Effects of L-arginine and L-NAME on ischemia-reperfusion in rat liver. Acta Cir Bras,2015,30(5):345-352.
[6] Chang NJ,Weng WH,Chang KH,et al.Genome-wide gene expression profiling of ischemia-reperfusion injury in rat kidney,intestine and skeletal muscle implicate a common involvement of MAPK signaling pathway. Mol Med Rep,2015,11(5):3786-3793.
[7] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 解放军医学杂志,2015,21(11):833-839.
[8] de Lourdes Jorge G,Dos Reis Tártaro R. Later evaluation of ischemia and reperfusion by the pringle maneuver in wistar rats,demonstrating that hepatic lesions can be reversible. Transplant Proc,2017,49(4):898-901.
[9] Guiu B,Chevallier P,Denys A,et al.Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy:the liver venous deprivation technique. Eur Radiol,2016,26(12):4259-4267.
[10] 薛帅,曾承,方泽鸿等. AMPK减轻肝脏缺血再灌注损伤作用的研究进展. 中华器官移植杂志,2017,38(5):312-315.
[11] Yoon SY,Kim CY,Han HJ,et al.Protective effect of ischemic postconditioning against hepatic ischemic reperfusion injury in rat liver. Ann Surg Treat Res,2015,88(5):241-245.
[12] Manne NDPK,Arvapalli R,Graffeo VA,et al.Prophylactic treatment with cerium oxide nanoparticles attenuate hepatic ischemia reperfusion injury in sprague dawley rats. Cell Physiol Biochem,2017,42(5):1837-1846.
[13] Gui B,Hua F,Chen J,et al.Protective effects of pretreatment with oleanolic acid in rats in the acute phase of hepatic ischemia-reperfusion injury:role of the PI3K/Akt pathway. Mediators Inflamm,2014,2014:451826.
[14] Kuroda S,Tashiro H,Kimura Y,et al.Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats. Liver Transpl,2015,21(1):123-131.
[15] Gonul Y,Ozsoy M,Kocak A,et al.Antioxidant, antiapoptotic and inflammatory effects of interleukin-18 binding protein on kidney damage induced by hepatic ischemia reperfusion. Am J Med Sci,2016,351(6):607-615.
[16] Wei LF,Zhang HM,Wang SS,et al.Changes of MDA and SOD in brain tissue after secondary brain injury with seawater immersion in rats. Turk Neurosurg,2016,26(3):384-388.
[17] Dong S,Cao Y,Li H,et al.Impact of ischemic preconditioning on ischemia-reperfusion injury of the rat sciatic nerve. Int J Clin Exp Med,2015,8(9):16245-16251.
[18] Brasoveanu V,Pautov M,Ionescu MI,et al.Ante-situm liver resection for giant hepatic tumour-case report and review of literature. Chirurgia (Bucur),2017,112(3):326-331.
[19] Kaur S,Siddiqui H,Bhat MH.Hepatic progenitor cells in action:liver regeneration or fibrosis. Am J Pathol,2015,185(9):2342-2450.
[20] Loregger A,Cook EC,Nelson JK,et al.A MARCH6 and IDOL E3 ubiquitin ligase circuit uncouples cholesterol synthesis from lipoprotein uptake in hepatocytes. Mol Cell Biol,2016,36(2):285-294.
[21] Grandadam S,Compagnon P,Arnaud A,et al.Role of preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma type III. Ann Surg Onco,2010,17(12):3155-3161.

门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*

Protective effect of aspartate ornithine on hepatic ischemic reperfusion injury in patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[4]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[5]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[6]	张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(5): 736-739.
[7]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[8]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[9]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[10]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[11]	王宝丹, 李萌, 高于. α-干扰素治疗慢性乙型肝炎儿童疗效及其影响疗效的因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 345-348.
[12]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[13]	徐曼曼, 陈煜, 李爽. 特利加压素联合白蛋白输注治疗肝肾综合征患者疗效及尿NGAL和KIM-1对疗效的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 385-388.
[14]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[15]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.